nodes	percent_of_prediction	percent_of_DWPC	metapath
Apixaban—ABCG2—Cladribine—multiple sclerosis	0.124	0.158	CbGbCtD
Apixaban—ABCG2—Mitoxantrone—multiple sclerosis	0.0907	0.115	CbGbCtD
Apixaban—ABCG2—Dexamethasone—multiple sclerosis	0.047	0.0598	CbGbCtD
Apixaban—ABCB1—Methylprednisolone—multiple sclerosis	0.0448	0.057	CbGbCtD
Apixaban—CYP3A4—Fingolimod—multiple sclerosis	0.0417	0.053	CbGbCtD
Apixaban—ABCG2—Methotrexate—multiple sclerosis	0.0378	0.0481	CbGbCtD
Apixaban—CYP2C19—Prednisone—multiple sclerosis	0.0337	0.0428	CbGbCtD
Apixaban—ABCB1—Mitoxantrone—multiple sclerosis	0.0327	0.0416	CbGbCtD
Apixaban—ABCB1—Betamethasone—multiple sclerosis	0.0292	0.0371	CbGbCtD
Apixaban—ABCB1—Prednisolone—multiple sclerosis	0.0288	0.0366	CbGbCtD
Apixaban—ABCB1—Prednisone—multiple sclerosis	0.0272	0.0346	CbGbCtD
Apixaban—CYP3A4—Methylprednisolone—multiple sclerosis	0.0269	0.0342	CbGbCtD
Apixaban—CYP3A5—Dexamethasone—multiple sclerosis	0.0261	0.0331	CbGbCtD
Apixaban—CYP2C8—Dexamethasone—multiple sclerosis	0.0251	0.0319	CbGbCtD
Apixaban—CYP2C19—Dexamethasone—multiple sclerosis	0.021	0.0267	CbGbCtD
Apixaban—CYP3A4—Triamcinolone—multiple sclerosis	0.0204	0.0259	CbGbCtD
Apixaban—CYP3A4—Mitoxantrone—multiple sclerosis	0.0196	0.0249	CbGbCtD
Apixaban—Haemorrhagic stroke—Fingolimod—multiple sclerosis	0.0192	0.126	CcSEcCtD
Apixaban—CYP2C9—Dexamethasone—multiple sclerosis	0.0175	0.0222	CbGbCtD
Apixaban—CYP3A4—Betamethasone—multiple sclerosis	0.0175	0.0222	CbGbCtD
Apixaban—CYP3A4—Prednisolone—multiple sclerosis	0.0172	0.0219	CbGbCtD
Apixaban—ABCB1—Dexamethasone—multiple sclerosis	0.017	0.0216	CbGbCtD
Apixaban—CYP3A4—Prednisone—multiple sclerosis	0.0163	0.0207	CbGbCtD
Apixaban—ABCB1—Methotrexate—multiple sclerosis	0.0136	0.0173	CbGbCtD
Apixaban—CYP3A4—Dexamethasone—multiple sclerosis	0.0102	0.0129	CbGbCtD
Apixaban—Cerebral haemorrhage—Fingolimod—multiple sclerosis	0.00537	0.0353	CcSEcCtD
Apixaban—Gamma-glutamyltransferase increased—Fingolimod—multiple sclerosis	0.00362	0.0237	CcSEcCtD
Apixaban—Haemorrhage intracranial—Mitoxantrone—multiple sclerosis	0.0027	0.0177	CcSEcCtD
Apixaban—Conjunctival haemorrhage—Dexamethasone—multiple sclerosis	0.00233	0.0153	CcSEcCtD
Apixaban—Conjunctival haemorrhage—Betamethasone—multiple sclerosis	0.00233	0.0153	CcSEcCtD
Apixaban—Petechiae—Cladribine—multiple sclerosis	0.00205	0.0135	CcSEcCtD
Apixaban—Liver function test abnormal—Fingolimod—multiple sclerosis	0.00199	0.0131	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Fingolimod—multiple sclerosis	0.00194	0.0128	CcSEcCtD
Apixaban—Contusion—Cladribine—multiple sclerosis	0.00193	0.0127	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Fingolimod—multiple sclerosis	0.0019	0.0125	CcSEcCtD
Apixaban—Blood bilirubin increased—Cladribine—multiple sclerosis	0.00178	0.0117	CcSEcCtD
Apixaban—Ecchymosis—Cladribine—multiple sclerosis	0.00152	0.01	CcSEcCtD
Apixaban—Menorrhagia—Mitoxantrone—multiple sclerosis	0.0015	0.00983	CcSEcCtD
Apixaban—Connective tissue disorder—Fingolimod—multiple sclerosis	0.00147	0.00963	CcSEcCtD
Apixaban—Eye disorder—Fingolimod—multiple sclerosis	0.0014	0.00916	CcSEcCtD
Apixaban—Angiopathy—Fingolimod—multiple sclerosis	0.00136	0.0089	CcSEcCtD
Apixaban—Gamma-glutamyltransferase increased—Mitoxantrone—multiple sclerosis	0.00135	0.00884	CcSEcCtD
Apixaban—Petechiae—Mitoxantrone—multiple sclerosis	0.00135	0.00884	CcSEcCtD
Apixaban—Mediastinal disorder—Fingolimod—multiple sclerosis	0.00135	0.00884	CcSEcCtD
Apixaban—Contusion—Mitoxantrone—multiple sclerosis	0.00127	0.00834	CcSEcCtD
Apixaban—Blood bilirubin increased—Mitoxantrone—multiple sclerosis	0.00117	0.00769	CcSEcCtD
Apixaban—Petechiae—Prednisolone—multiple sclerosis	0.00111	0.00725	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.0011	0.00722	CcSEcCtD
Apixaban—Nervous system disorder—Fingolimod—multiple sclerosis	0.00104	0.00683	CcSEcCtD
Apixaban—Skin disorder—Fingolimod—multiple sclerosis	0.00103	0.00677	CcSEcCtD
Apixaban—Petechiae—Triamcinolone—multiple sclerosis	0.00102	0.00667	CcSEcCtD
Apixaban—Petechiae—Methylprednisolone—multiple sclerosis	0.00101	0.00666	CcSEcCtD
Apixaban—Ecchymosis—Mitoxantrone—multiple sclerosis	0.001	0.00658	CcSEcCtD
Apixaban—Hypotension—Fingolimod—multiple sclerosis	0.000992	0.00651	CcSEcCtD
Apixaban—Petechiae—Dexamethasone—multiple sclerosis	0.000922	0.00605	CcSEcCtD
Apixaban—Petechiae—Betamethasone—multiple sclerosis	0.000922	0.00605	CcSEcCtD
Apixaban—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.000916	0.00601	CcSEcCtD
Apixaban—Hepatobiliary disease—Cladribine—multiple sclerosis	0.000892	0.00586	CcSEcCtD
Apixaban—Epistaxis—Cladribine—multiple sclerosis	0.00089	0.00584	CcSEcCtD
Apixaban—Contusion—Dexamethasone—multiple sclerosis	0.000869	0.00571	CcSEcCtD
Apixaban—Contusion—Betamethasone—multiple sclerosis	0.000869	0.00571	CcSEcCtD
Apixaban—Haemoglobin—Cladribine—multiple sclerosis	0.000851	0.00559	CcSEcCtD
Apixaban—Haemorrhage—Cladribine—multiple sclerosis	0.000847	0.00556	CcSEcCtD
Apixaban—Urinary tract disorder—Cladribine—multiple sclerosis	0.000836	0.00549	CcSEcCtD
Apixaban—Connective tissue disorder—Cladribine—multiple sclerosis	0.000832	0.00546	CcSEcCtD
Apixaban—Urethral disorder—Cladribine—multiple sclerosis	0.00083	0.00545	CcSEcCtD
Apixaban—Ecchymosis—Prednisolone—multiple sclerosis	0.000822	0.0054	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Mitoxantrone—multiple sclerosis	0.000804	0.00528	CcSEcCtD
Apixaban—Petechiae—Prednisone—multiple sclerosis	0.000803	0.00527	CcSEcCtD
Apixaban—Haematemesis—Methotrexate—multiple sclerosis	0.000795	0.00522	CcSEcCtD
Apixaban—Eye disorder—Cladribine—multiple sclerosis	0.000791	0.00519	CcSEcCtD
Apixaban—Angiopathy—Cladribine—multiple sclerosis	0.000768	0.00504	CcSEcCtD
Apixaban—Immune system disorder—Cladribine—multiple sclerosis	0.000765	0.00502	CcSEcCtD
Apixaban—Mediastinal disorder—Cladribine—multiple sclerosis	0.000763	0.00501	CcSEcCtD
Apixaban—Diabetes mellitus—Prednisolone—multiple sclerosis	0.000759	0.00498	CcSEcCtD
Apixaban—Contusion—Prednisone—multiple sclerosis	0.000757	0.00497	CcSEcCtD
Apixaban—Ecchymosis—Triamcinolone—multiple sclerosis	0.000756	0.00496	CcSEcCtD
Apixaban—Ecchymosis—Methylprednisolone—multiple sclerosis	0.000754	0.00495	CcSEcCtD
Apixaban—Hepatobiliary disease—Azathioprine—multiple sclerosis	0.000725	0.00476	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000724	0.00476	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000709	0.00466	CcSEcCtD
Apixaban—Dizziness—Fingolimod—multiple sclerosis	0.000702	0.00461	CcSEcCtD
Apixaban—Diabetes mellitus—Triamcinolone—multiple sclerosis	0.000698	0.00458	CcSEcCtD
Apixaban—Diabetes mellitus—Methylprednisolone—multiple sclerosis	0.000696	0.00457	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Methylprednisolone—multiple sclerosis	0.000696	0.00457	CcSEcCtD
Apixaban—Haemoglobin—Azathioprine—multiple sclerosis	0.000692	0.00454	CcSEcCtD
Apixaban—Haemorrhage—Azathioprine—multiple sclerosis	0.000688	0.00452	CcSEcCtD
Apixaban—Ecchymosis—Dexamethasone—multiple sclerosis	0.000686	0.0045	CcSEcCtD
Apixaban—Ecchymosis—Betamethasone—multiple sclerosis	0.000686	0.0045	CcSEcCtD
Apixaban—Anaemia—Cladribine—multiple sclerosis	0.000681	0.00447	CcSEcCtD
Apixaban—Petechiae—Methotrexate—multiple sclerosis	0.000671	0.00441	CcSEcCtD
Apixaban—Diabetes mellitus—Dexamethasone—multiple sclerosis	0.000633	0.00416	CcSEcCtD
Apixaban—Diabetes mellitus—Betamethasone—multiple sclerosis	0.000633	0.00416	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000623	0.00409	CcSEcCtD
Apixaban—Immune system disorder—Azathioprine—multiple sclerosis	0.000622	0.00408	CcSEcCtD
Apixaban—Mediastinal disorder—Azathioprine—multiple sclerosis	0.00062	0.00407	CcSEcCtD
Apixaban—Ecchymosis—Prednisone—multiple sclerosis	0.000597	0.00392	CcSEcCtD
Apixaban—Haematuria—Mitoxantrone—multiple sclerosis	0.000591	0.00388	CcSEcCtD
Apixaban—Nervous system disorder—Cladribine—multiple sclerosis	0.00059	0.00387	CcSEcCtD
Apixaban—Thrombocytopenia—Cladribine—multiple sclerosis	0.000589	0.00387	CcSEcCtD
Apixaban—Skin disorder—Cladribine—multiple sclerosis	0.000584	0.00384	CcSEcCtD
Apixaban—Hypotension—Cladribine—multiple sclerosis	0.000562	0.00369	CcSEcCtD
Apixaban—Haemoglobin—Mitoxantrone—multiple sclerosis	0.000559	0.00367	CcSEcCtD
Apixaban—Haemorrhage—Mitoxantrone—multiple sclerosis	0.000557	0.00365	CcSEcCtD
Apixaban—Anaemia—Azathioprine—multiple sclerosis	0.000554	0.00364	CcSEcCtD
Apixaban—Diabetes mellitus—Prednisone—multiple sclerosis	0.000551	0.00362	CcSEcCtD
Apixaban—Breast disorder—Methylprednisolone—multiple sclerosis	0.000547	0.00359	CcSEcCtD
Apixaban—Melaena—Methotrexate—multiple sclerosis	0.000539	0.00354	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.000534	0.00351	CcSEcCtD
Apixaban—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000519	0.00341	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000507	0.00333	CcSEcCtD
Apixaban—Ecchymosis—Methotrexate—multiple sclerosis	0.000499	0.00328	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Prednisone—multiple sclerosis	0.00048	0.00315	CcSEcCtD
Apixaban—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000479	0.00314	CcSEcCtD
Apixaban—Skin disorder—Azathioprine—multiple sclerosis	0.000475	0.00312	CcSEcCtD
Apixaban—Diabetes mellitus—Methotrexate—multiple sclerosis	0.000461	0.00302	CcSEcCtD
Apixaban—Haemoglobin—Prednisolone—multiple sclerosis	0.000459	0.00301	CcSEcCtD
Apixaban—Hypotension—Azathioprine—multiple sclerosis	0.000457	0.003	CcSEcCtD
Apixaban—Haemorrhage—Prednisolone—multiple sclerosis	0.000457	0.003	CcSEcCtD
Apixaban—Anaemia—Mitoxantrone—multiple sclerosis	0.000448	0.00294	CcSEcCtD
Apixaban—Hypersensitivity—Cladribine—multiple sclerosis	0.000443	0.00291	CcSEcCtD
Apixaban—Epistaxis—Triamcinolone—multiple sclerosis	0.000441	0.0029	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000423	0.00278	CcSEcCtD
Apixaban—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000422	0.00277	CcSEcCtD
Apixaban—Haemoglobin—Triamcinolone—multiple sclerosis	0.000422	0.00277	CcSEcCtD
Apixaban—Haemoglobin—Methylprednisolone—multiple sclerosis	0.000421	0.00276	CcSEcCtD
Apixaban—Haemorrhage—Triamcinolone—multiple sclerosis	0.00042	0.00276	CcSEcCtD
Apixaban—Haemorrhage—Methylprednisolone—multiple sclerosis	0.000419	0.00275	CcSEcCtD
Apixaban—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000412	0.0027	CcSEcCtD
Apixaban—Dizziness—Cladribine—multiple sclerosis	0.000398	0.00261	CcSEcCtD
Apixaban—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000395	0.0026	CcSEcCtD
Apixaban—Eye disorder—Methylprednisolone—multiple sclerosis	0.000391	0.00257	CcSEcCtD
Apixaban—Shock—Mitoxantrone—multiple sclerosis	0.000389	0.00255	CcSEcCtD
Apixaban—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000387	0.00254	CcSEcCtD
Apixaban—Skin disorder—Mitoxantrone—multiple sclerosis	0.000384	0.00252	CcSEcCtD
Apixaban—Haemoglobin—Dexamethasone—multiple sclerosis	0.000383	0.00251	CcSEcCtD
Apixaban—Haemoglobin—Betamethasone—multiple sclerosis	0.000383	0.00251	CcSEcCtD
Apixaban—Haemorrhage—Betamethasone—multiple sclerosis	0.000381	0.0025	CcSEcCtD
Apixaban—Haemorrhage—Dexamethasone—multiple sclerosis	0.000381	0.0025	CcSEcCtD
Apixaban—Angiopathy—Methylprednisolone—multiple sclerosis	0.00038	0.0025	CcSEcCtD
Apixaban—Rash—Cladribine—multiple sclerosis	0.000379	0.00249	CcSEcCtD
Apixaban—Dermatitis—Cladribine—multiple sclerosis	0.000379	0.00249	CcSEcCtD
Apixaban—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000378	0.00248	CcSEcCtD
Apixaban—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000378	0.00248	CcSEcCtD
Apixaban—Liver function test abnormal—Methotrexate—multiple sclerosis	0.00037	0.00243	CcSEcCtD
Apixaban—Hypotension—Mitoxantrone—multiple sclerosis	0.000369	0.00243	CcSEcCtD
Apixaban—Breast disorder—Methotrexate—multiple sclerosis	0.000362	0.00238	CcSEcCtD
Apixaban—Hypersensitivity—Azathioprine—multiple sclerosis	0.00036	0.00237	CcSEcCtD
Apixaban—Nausea—Cladribine—multiple sclerosis	0.000357	0.00235	CcSEcCtD
Apixaban—Syncope—Prednisolone—multiple sclerosis	0.000356	0.00234	CcSEcCtD
Apixaban—Eye disorder—Betamethasone—multiple sclerosis	0.000356	0.00234	CcSEcCtD
Apixaban—Eye disorder—Dexamethasone—multiple sclerosis	0.000356	0.00234	CcSEcCtD
Apixaban—Loss of consciousness—Prednisolone—multiple sclerosis	0.000349	0.00229	CcSEcCtD
Apixaban—Angiopathy—Dexamethasone—multiple sclerosis	0.000346	0.00227	CcSEcCtD
Apixaban—Angiopathy—Betamethasone—multiple sclerosis	0.000346	0.00227	CcSEcCtD
Apixaban—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000341	0.00554	CbGpPWpGaD
Apixaban—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000341	0.00554	CbGpPWpGaD
Apixaban—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000337	0.00546	CbGpPWpGaD
Apixaban—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000337	0.00546	CbGpPWpGaD
Apixaban—Haemoglobin—Prednisone—multiple sclerosis	0.000333	0.00219	CcSEcCtD
Apixaban—Haemorrhage—Prednisone—multiple sclerosis	0.000332	0.00218	CcSEcCtD
Apixaban—Syncope—Triamcinolone—multiple sclerosis	0.000328	0.00215	CcSEcCtD
Apixaban—Syncope—Methylprednisolone—multiple sclerosis	0.000327	0.00215	CcSEcCtD
Apixaban—Connective tissue disorder—Prednisone—multiple sclerosis	0.000326	0.00214	CcSEcCtD
Apixaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000325	0.00527	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000325	0.00527	CbGpPWpGaD
Apixaban—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000324	0.00213	CcSEcCtD
Apixaban—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000324	0.00525	CbGpPWpGaD
Apixaban—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000324	0.00525	CbGpPWpGaD
Apixaban—Dizziness—Azathioprine—multiple sclerosis	0.000323	0.00212	CcSEcCtD
Apixaban—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000321	0.00211	CcSEcCtD
Apixaban—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000321	0.0021	CcSEcCtD
Apixaban—Shock—Prednisolone—multiple sclerosis	0.000319	0.00209	CcSEcCtD
Apixaban—Eye disorder—Prednisone—multiple sclerosis	0.00031	0.00204	CcSEcCtD
Apixaban—Rash—Azathioprine—multiple sclerosis	0.000308	0.00202	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000308	0.00202	CcSEcCtD
Apixaban—Dermatitis—Azathioprine—multiple sclerosis	0.000308	0.00202	CcSEcCtD
Apixaban—Angiopathy—Prednisone—multiple sclerosis	0.000301	0.00198	CcSEcCtD
Apixaban—Immune system disorder—Prednisone—multiple sclerosis	0.0003	0.00197	CcSEcCtD
Apixaban—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000298	0.00196	CcSEcCtD
Apixaban—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000298	0.00195	CcSEcCtD
Apixaban—Syncope—Betamethasone—multiple sclerosis	0.000297	0.00195	CcSEcCtD
Apixaban—Syncope—Dexamethasone—multiple sclerosis	0.000297	0.00195	CcSEcCtD
Apixaban—F10—Hemostasis—PLEK—multiple sclerosis	0.000296	0.0048	CbGpPWpGaD
Apixaban—Haematuria—Methotrexate—multiple sclerosis	0.000294	0.00193	CcSEcCtD
Apixaban—Shock—Triamcinolone—multiple sclerosis	0.000293	0.00193	CcSEcCtD
Apixaban—Shock—Methylprednisolone—multiple sclerosis	0.000293	0.00192	CcSEcCtD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000293	0.00475	CbGpPWpGaD
Apixaban—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000292	0.00192	CcSEcCtD
Apixaban—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000292	0.00192	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—C4A—multiple sclerosis	0.000292	0.00473	CbGpPWpGaD
Apixaban—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000291	0.00191	CcSEcCtD
Apixaban—Loss of consciousness—Betamethasone—multiple sclerosis	0.000291	0.00191	CcSEcCtD
Apixaban—Epistaxis—Methotrexate—multiple sclerosis	0.000291	0.00191	CcSEcCtD
Apixaban—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000291	0.00191	CcSEcCtD
Apixaban—Nausea—Azathioprine—multiple sclerosis	0.000291	0.00191	CcSEcCtD
Apixaban—Skin disorder—Methylprednisolone—multiple sclerosis	0.000289	0.0019	CcSEcCtD
Apixaban—Haemoglobin—Methotrexate—multiple sclerosis	0.000279	0.00183	CcSEcCtD
Apixaban—Hypotension—Methylprednisolone—multiple sclerosis	0.000278	0.00183	CcSEcCtD
Apixaban—Haemorrhage—Methotrexate—multiple sclerosis	0.000277	0.00182	CcSEcCtD
Apixaban—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000277	0.00449	CbGpPWpGaD
Apixaban—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000277	0.00449	CbGpPWpGaD
Apixaban—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000274	0.0018	CcSEcCtD
Apixaban—Urethral disorder—Methotrexate—multiple sclerosis	0.000272	0.00178	CcSEcCtD
Apixaban—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000271	0.00178	CcSEcCtD
Apixaban—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000271	0.00178	CcSEcCtD
Apixaban—Anaemia—Prednisone—multiple sclerosis	0.000267	0.00175	CcSEcCtD
Apixaban—Shock—Dexamethasone—multiple sclerosis	0.000266	0.00175	CcSEcCtD
Apixaban—Shock—Betamethasone—multiple sclerosis	0.000266	0.00175	CcSEcCtD
Apixaban—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000265	0.00174	CcSEcCtD
Apixaban—Nervous system disorder—Betamethasone—multiple sclerosis	0.000265	0.00174	CcSEcCtD
Apixaban—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000265	0.00174	CcSEcCtD
Apixaban—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000265	0.00174	CcSEcCtD
Apixaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000263	0.00427	CbGpPWpGaD
Apixaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000263	0.00427	CbGpPWpGaD
Apixaban—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00026	0.00422	CbGpPWpGaD
Apixaban—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00026	0.00422	CbGpPWpGaD
Apixaban—Eye disorder—Methotrexate—multiple sclerosis	0.000259	0.0017	CcSEcCtD
Apixaban—Syncope—Prednisone—multiple sclerosis	0.000259	0.0017	CcSEcCtD
Apixaban—Loss of consciousness—Prednisone—multiple sclerosis	0.000254	0.00167	CcSEcCtD
Apixaban—Hypotension—Dexamethasone—multiple sclerosis	0.000253	0.00166	CcSEcCtD
Apixaban—Hypotension—Betamethasone—multiple sclerosis	0.000253	0.00166	CcSEcCtD
Apixaban—Angiopathy—Methotrexate—multiple sclerosis	0.000252	0.00165	CcSEcCtD
Apixaban—Immune system disorder—Methotrexate—multiple sclerosis	0.00025	0.00164	CcSEcCtD
Apixaban—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00025	0.00164	CcSEcCtD
Apixaban—Rash—Mitoxantrone—multiple sclerosis	0.000249	0.00164	CcSEcCtD
Apixaban—Dermatitis—Mitoxantrone—multiple sclerosis	0.000249	0.00163	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000244	0.0016	CcSEcCtD
Apixaban—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000244	0.00396	CbGpPWpGaD
Apixaban—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000244	0.00396	CbGpPWpGaD
Apixaban—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000241	0.0039	CbGpPWpGaD
Apixaban—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000241	0.0039	CbGpPWpGaD
Apixaban—Hypersensitivity—Prednisolone—multiple sclerosis	0.000239	0.00157	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000238	0.00386	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000238	0.00386	CbGpPWpGaD
Apixaban—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000236	0.00383	CbGpPWpGaD
Apixaban—Anaphylactic shock—Prednisone—multiple sclerosis	0.000236	0.00155	CcSEcCtD
Apixaban—Nausea—Mitoxantrone—multiple sclerosis	0.000235	0.00154	CcSEcCtD
Apixaban—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000234	0.00153	CcSEcCtD
Apixaban—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000234	0.00153	CcSEcCtD
Apixaban—F10—Metabolism of proteins—SLC30A7—multiple sclerosis	0.000233	0.00377	CbGpPWpGaD
Apixaban—Shock—Prednisone—multiple sclerosis	0.000232	0.00152	CcSEcCtD
Apixaban—Nervous system disorder—Prednisone—multiple sclerosis	0.000231	0.00152	CcSEcCtD
Apixaban—Skin disorder—Prednisone—multiple sclerosis	0.000229	0.0015	CcSEcCtD
Apixaban—Anaemia—Methotrexate—multiple sclerosis	0.000223	0.00146	CcSEcCtD
Apixaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00022	0.00357	CbGpPWpGaD
Apixaban—Hypersensitivity—Triamcinolone—multiple sclerosis	0.00022	0.00144	CcSEcCtD
Apixaban—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000219	0.00144	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000216	0.00351	CbGpPWpGaD
Apixaban—Dizziness—Prednisolone—multiple sclerosis	0.000214	0.00141	CcSEcCtD
Apixaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000214	0.00346	CbGpPWpGaD
Apixaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000214	0.00346	CbGpPWpGaD
Apixaban—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.000211	0.00343	CbGpPWpGaD
Apixaban—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.000211	0.00343	CbGpPWpGaD
Apixaban—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000208	0.00338	CbGpPWpGaD
Apixaban—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000208	0.00338	CbGpPWpGaD
Apixaban—F10—Hemostasis—SELE—multiple sclerosis	0.000208	0.00338	CbGpPWpGaD
Apixaban—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000206	0.00334	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—SRM—multiple sclerosis	0.000205	0.00333	CbGpPWpGaD
Apixaban—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000205	0.00333	CbGpPWpGaD
Apixaban—Rash—Prednisolone—multiple sclerosis	0.000205	0.00134	CcSEcCtD
Apixaban—Dermatitis—Prednisolone—multiple sclerosis	0.000204	0.00134	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000204	0.00134	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000204	0.00331	CbGpPWpGaD
Apixaban—Dizziness—Triamcinolone—multiple sclerosis	0.000197	0.00129	CcSEcCtD
Apixaban—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000197	0.00129	CcSEcCtD
Apixaban—Dizziness—Methylprednisolone—multiple sclerosis	0.000197	0.00129	CcSEcCtD
Apixaban—Nervous system disorder—Methotrexate—multiple sclerosis	0.000193	0.00127	CcSEcCtD
Apixaban—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000193	0.00127	CcSEcCtD
Apixaban—Nausea—Prednisolone—multiple sclerosis	0.000193	0.00126	CcSEcCtD
Apixaban—Skin disorder—Methotrexate—multiple sclerosis	0.000191	0.00126	CcSEcCtD
Apixaban—CYP2J2—Biological oxidations—POMC—multiple sclerosis	0.00019	0.00309	CbGpPWpGaD
Apixaban—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000189	0.00306	CbGpPWpGaD
Apixaban—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000189	0.00306	CbGpPWpGaD
Apixaban—F10—Metabolism of proteins—PABPC1—multiple sclerosis	0.000188	0.00305	CbGpPWpGaD
Apixaban—Rash—Triamcinolone—multiple sclerosis	0.000188	0.00123	CcSEcCtD
Apixaban—Dermatitis—Triamcinolone—multiple sclerosis	0.000188	0.00123	CcSEcCtD
Apixaban—Rash—Methylprednisolone—multiple sclerosis	0.000188	0.00123	CcSEcCtD
Apixaban—Dermatitis—Methylprednisolone—multiple sclerosis	0.000187	0.00123	CcSEcCtD
Apixaban—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000186	0.00302	CbGpPWpGaD
Apixaban—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000186	0.00302	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.000185	0.00301	CbGpPWpGaD
Apixaban—Hypotension—Methotrexate—multiple sclerosis	0.000184	0.00121	CcSEcCtD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000184	0.00298	CbGpPWpGaD
Apixaban—Dizziness—Betamethasone—multiple sclerosis	0.000179	0.00117	CcSEcCtD
Apixaban—Dizziness—Dexamethasone—multiple sclerosis	0.000179	0.00117	CcSEcCtD
Apixaban—Nausea—Triamcinolone—multiple sclerosis	0.000177	0.00116	CcSEcCtD
Apixaban—Nausea—Methylprednisolone—multiple sclerosis	0.000177	0.00116	CcSEcCtD
Apixaban—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000176	0.00285	CbGpPWpGaD
Apixaban—Hypersensitivity—Prednisone—multiple sclerosis	0.000174	0.00114	CcSEcCtD
Apixaban—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000172	0.00279	CbGpPWpGaD
Apixaban—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000172	0.00279	CbGpPWpGaD
Apixaban—Rash—Betamethasone—multiple sclerosis	0.000171	0.00112	CcSEcCtD
Apixaban—Rash—Dexamethasone—multiple sclerosis	0.000171	0.00112	CcSEcCtD
Apixaban—Dermatitis—Dexamethasone—multiple sclerosis	0.00017	0.00112	CcSEcCtD
Apixaban—Dermatitis—Betamethasone—multiple sclerosis	0.00017	0.00112	CcSEcCtD
Apixaban—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00017	0.00112	CcSEcCtD
Apixaban—F10—Metabolism of proteins—RPL5—multiple sclerosis	0.00017	0.00275	CbGpPWpGaD
Apixaban—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00017	0.00275	CbGpPWpGaD
Apixaban—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00017	0.00275	CbGpPWpGaD
Apixaban—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000162	0.00263	CbGpPWpGaD
Apixaban—Nausea—Dexamethasone—multiple sclerosis	0.000161	0.00106	CcSEcCtD
Apixaban—Nausea—Betamethasone—multiple sclerosis	0.000161	0.00106	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000161	0.00261	CbGpPWpGaD
Apixaban—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.00016	0.00259	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000156	0.00253	CbGpPWpGaD
Apixaban—Dizziness—Prednisone—multiple sclerosis	0.000156	0.00102	CcSEcCtD
Apixaban—F10—Hemostasis—ITGA4—multiple sclerosis	0.000151	0.00244	CbGpPWpGaD
Apixaban—F10—Hemostasis—IFNB1—multiple sclerosis	0.00015	0.00243	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000149	0.00242	CbGpPWpGaD
Apixaban—Rash—Prednisone—multiple sclerosis	0.000149	0.000976	CcSEcCtD
Apixaban—Dermatitis—Prednisone—multiple sclerosis	0.000148	0.000975	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000148	0.0024	CbGpPWpGaD
Apixaban—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000147	0.00238	CbGpPWpGaD
Apixaban—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000147	0.00238	CbGpPWpGaD
Apixaban—Hypersensitivity—Methotrexate—multiple sclerosis	0.000145	0.000953	CcSEcCtD
Apixaban—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000145	0.00235	CbGpPWpGaD
Apixaban—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000145	0.00235	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—CYP27B1—multiple sclerosis	0.000145	0.00235	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—CYP24A1—multiple sclerosis	0.000145	0.00235	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000142	0.00231	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000142	0.0023	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.00014	0.00228	CbGpPWpGaD
Apixaban—Nausea—Prednisone—multiple sclerosis	0.00014	0.000919	CcSEcCtD
Apixaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000136	0.0022	CbGpPWpGaD
Apixaban—ABCG2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000134	0.00217	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—GPC5—multiple sclerosis	0.000132	0.00215	CbGpPWpGaD
Apixaban—Dizziness—Methotrexate—multiple sclerosis	0.00013	0.000855	CcSEcCtD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000128	0.00208	CbGpPWpGaD
Apixaban—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000127	0.00207	CbGpPWpGaD
Apixaban—F10—Metabolism of proteins—BCHE—multiple sclerosis	0.000124	0.00201	CbGpPWpGaD
Apixaban—Rash—Methotrexate—multiple sclerosis	0.000124	0.000815	CcSEcCtD
Apixaban—Dermatitis—Methotrexate—multiple sclerosis	0.000124	0.000815	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000124	0.00201	CbGpPWpGaD
Apixaban—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	0.000121	0.00196	CbGpPWpGaD
Apixaban—Nausea—Methotrexate—multiple sclerosis	0.000117	0.000768	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.000116	0.00188	CbGpPWpGaD
Apixaban—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000113	0.00184	CbGpPWpGaD
Apixaban—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000113	0.00184	CbGpPWpGaD
Apixaban—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000112	0.00181	CbGpPWpGaD
Apixaban—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000112	0.00181	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—CD86—multiple sclerosis	0.000111	0.00181	CbGpPWpGaD
Apixaban—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.00011	0.00179	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—RRM1—multiple sclerosis	0.00011	0.00178	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IL10—multiple sclerosis	0.000109	0.00177	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	0.000109	0.00177	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IL4—multiple sclerosis	0.000106	0.00172	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	0.000104	0.00168	CbGpPWpGaD
Apixaban—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000103	0.00168	CbGpPWpGaD
Apixaban—F10—Hemostasis—IL2RA—multiple sclerosis	0.000103	0.00167	CbGpPWpGaD
Apixaban—ABCG2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000101	0.00164	CbGpPWpGaD
Apixaban—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.85e-05	0.0016	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—FAS—multiple sclerosis	9.79e-05	0.00159	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	9.73e-05	0.00158	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	9.62e-05	0.00156	CbGpPWpGaD
Apixaban—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.99e-05	0.00146	CbGpPWpGaD
Apixaban—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.95e-05	0.00145	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	8.79e-05	0.00143	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.51e-05	0.00138	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—SRM—multiple sclerosis	8.27e-05	0.00134	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—CD80—multiple sclerosis	8.12e-05	0.00132	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	8.12e-05	0.00132	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	8.12e-05	0.00132	CbGpPWpGaD
Apixaban—ABCG2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	8.01e-05	0.0013	CbGpPWpGaD
Apixaban—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.99e-05	0.0013	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	7.9e-05	0.00128	CbGpPWpGaD
Apixaban—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.68e-05	0.00125	CbGpPWpGaD
Apixaban—F10—Hemostasis—ALB—multiple sclerosis	7.44e-05	0.00121	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.31e-05	0.00119	CbGpPWpGaD
Apixaban—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.28e-05	0.00118	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.24e-05	0.00117	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.24e-05	0.00117	CbGpPWpGaD
Apixaban—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	7.23e-05	0.00117	CbGpPWpGaD
Apixaban—ABCG2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	7.08e-05	0.00115	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	7.05e-05	0.00114	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	7.03e-05	0.00114	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	7.02e-05	0.00114	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.67e-05	0.00108	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.61e-05	0.00107	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.61e-05	0.00107	CbGpPWpGaD
Apixaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	6.54e-05	0.00106	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	6.42e-05	0.00104	CbGpPWpGaD
Apixaban—F10—Metabolism of proteins—POMC—multiple sclerosis	6.42e-05	0.00104	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—BCHE—multiple sclerosis	6.3e-05	0.00102	CbGpPWpGaD
Apixaban—F10—Metabolism of proteins—CCL2—multiple sclerosis	6.28e-05	0.00102	CbGpPWpGaD
Apixaban—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.22e-05	0.00101	CbGpPWpGaD
Apixaban—F10—Hemostasis—IL2—multiple sclerosis	6.03e-05	0.000978	CbGpPWpGaD
Apixaban—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.93e-05	0.000961	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—SRM—multiple sclerosis	5.92e-05	0.000961	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—CYP24A1—multiple sclerosis	5.82e-05	0.000945	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—CYP27B1—multiple sclerosis	5.82e-05	0.000945	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	5.73e-05	0.000929	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IL2—multiple sclerosis	5.71e-05	0.000926	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	5.64e-05	0.000916	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.64e-05	0.000916	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.64e-05	0.000916	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	5.49e-05	0.00089	CbGpPWpGaD
Apixaban—CYP3A5—Biological oxidations—POMC—multiple sclerosis	5.49e-05	0.00089	CbGpPWpGaD
Apixaban—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.48e-05	0.000889	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	5.48e-05	0.000888	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	5.37e-05	0.000871	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—GPC5—multiple sclerosis	5.33e-05	0.000864	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—SRM—multiple sclerosis	5.13e-05	0.000832	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	5.11e-05	0.000829	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	5.11e-05	0.000829	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.83e-05	0.000784	CbGpPWpGaD
Apixaban—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.8e-05	0.000779	CbGpPWpGaD
Apixaban—CYP2C8—Biological oxidations—POMC—multiple sclerosis	4.75e-05	0.000771	CbGpPWpGaD
Apixaban—F10—Hemostasis—TGFB1—multiple sclerosis	4.71e-05	0.000763	CbGpPWpGaD
Apixaban—F10—Hemostasis—MAPK1—multiple sclerosis	4.61e-05	0.000748	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—SRM—multiple sclerosis	4.58e-05	0.000743	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—SRM—multiple sclerosis	4.47e-05	0.000725	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	4.45e-05	0.000722	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—RRM1—multiple sclerosis	4.41e-05	0.000716	CbGpPWpGaD
Apixaban—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.33e-05	0.000703	CbGpPWpGaD
Apixaban—CYP2C19—Biological oxidations—POMC—multiple sclerosis	4.24e-05	0.000688	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—SRM—multiple sclerosis	4.18e-05	0.000677	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	4.17e-05	0.000677	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	4.17e-05	0.000677	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—TNF—multiple sclerosis	4.16e-05	0.000674	CbGpPWpGaD
Apixaban—CYP2C9—Biological oxidations—POMC—multiple sclerosis	3.87e-05	0.000628	CbGpPWpGaD
Apixaban—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.83e-05	0.000621	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—GPC5—multiple sclerosis	3.82e-05	0.000619	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—APOE—multiple sclerosis	3.79e-05	0.000615	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	3.61e-05	0.000586	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	3.61e-05	0.000586	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—SRM—multiple sclerosis	3.57e-05	0.000579	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.53e-05	0.000573	CbGpPWpGaD
Apixaban—CYP1A2—Biological oxidations—POMC—multiple sclerosis	3.31e-05	0.000536	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—GPC5—multiple sclerosis	3.31e-05	0.000536	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—POMC—multiple sclerosis	3.26e-05	0.000528	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	3.23e-05	0.000523	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	3.23e-05	0.000523	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—RRM1—multiple sclerosis	3.16e-05	0.000513	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.15e-05	0.000511	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CYP24A1—multiple sclerosis	3.15e-05	0.000511	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CYP27B1—multiple sclerosis	3.15e-05	0.000511	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—ALB—multiple sclerosis	2.97e-05	0.000482	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.95e-05	0.000479	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.94e-05	0.000477	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.94e-05	0.000477	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GPC5—multiple sclerosis	2.88e-05	0.000467	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.88e-05	0.000466	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—SRM—multiple sclerosis	2.75e-05	0.000447	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—RRM1—multiple sclerosis	2.74e-05	0.000444	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GPC5—multiple sclerosis	2.69e-05	0.000436	CbGpPWpGaD
Apixaban—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.55e-05	0.000414	CbGpPWpGaD
Apixaban—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.55e-05	0.000414	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—BCHE—multiple sclerosis	2.54e-05	0.000411	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	2.51e-05	0.000408	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	2.51e-05	0.000408	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.46e-05	0.000399	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—RRM1—multiple sclerosis	2.44e-05	0.000397	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—RRM1—multiple sclerosis	2.39e-05	0.000387	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GPC5—multiple sclerosis	2.3e-05	0.000373	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—RRM1—multiple sclerosis	2.23e-05	0.000362	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.2e-05	0.000357	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.2e-05	0.000356	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.15e-05	0.000349	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.13e-05	0.000345	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.05e-05	0.000333	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.94e-05	0.000315	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.94e-05	0.000315	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.91e-05	0.000309	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.9e-05	0.000308	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.83e-05	0.000296	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.82e-05	0.000295	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.77e-05	0.000288	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.73e-05	0.000281	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.66e-05	0.00027	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.63e-05	0.000264	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.57e-05	0.000255	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—APOE—multiple sclerosis	1.53e-05	0.000247	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.49e-05	0.000241	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.49e-05	0.000241	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.48e-05	0.00024	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.47e-05	0.000238	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.4e-05	0.000228	CbGpPWpGaD
Apixaban—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.38e-05	0.000224	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—BCHE—multiple sclerosis	1.37e-05	0.000222	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.35e-05	0.00022	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—POMC—multiple sclerosis	1.31e-05	0.000213	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.28e-05	0.000208	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.27e-05	0.000206	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—ALB—multiple sclerosis	1.19e-05	0.000194	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.16e-05	0.000188	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—BCHE—multiple sclerosis	1.09e-05	0.000177	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—APOE—multiple sclerosis	1.09e-05	0.000177	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—APOE—multiple sclerosis	9.46e-06	0.000154	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—POMC—multiple sclerosis	9.39e-06	0.000152	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—ALB—multiple sclerosis	8.56e-06	0.000139	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—APOE—multiple sclerosis	8.45e-06	0.000137	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—BCHE—multiple sclerosis	8.44e-06	0.000137	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—APOE—multiple sclerosis	8.25e-06	0.000134	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—POMC—multiple sclerosis	8.13e-06	0.000132	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—APOE—multiple sclerosis	7.7e-06	0.000125	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—ALB—multiple sclerosis	7.41e-06	0.00012	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—POMC—multiple sclerosis	7.26e-06	0.000118	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—POMC—multiple sclerosis	7.08e-06	0.000115	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—POMC—multiple sclerosis	6.62e-06	0.000107	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—ALB—multiple sclerosis	6.62e-06	0.000107	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—APOE—multiple sclerosis	6.58e-06	0.000107	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—ALB—multiple sclerosis	6.46e-06	0.000105	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—ALB—multiple sclerosis	6.03e-06	9.79e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—POMC—multiple sclerosis	5.65e-06	9.17e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—ALB—multiple sclerosis	5.16e-06	8.36e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—APOE—multiple sclerosis	5.08e-06	8.24e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—POMC—multiple sclerosis	4.36e-06	7.08e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—ALB—multiple sclerosis	3.98e-06	6.45e-05	CbGpPWpGaD
